Big data from the National Health Insurance was found to have been used to evaluate the safety of JAK inhibitors, based on which its use has been restricted in high-risk patients in Korea. This is the first time that NHI big data had been used for safety evaluation of pharmaceuticals in Korea.

The National Health Insurance Service’s Big Data Strategy Headquarters held a press conference with the press corp on the 1st at its Wonju headquarters to deliver this news.

Soon-Ae Shin, Deputy Minister of the NHIS Big Data Headquarters, said, “We established a consultative body with the Ministry of Food and Drug Safety to conduct joint research on information related to the real use of pharmace